https://www.inovalon.com/publications/use-of-screening-tools-and-patterns-of-healthcare-utilization-among-pregnant-women-diagnosed-with-preterm-labor-in-the-u-s-emergency-department-setting/ 2017-05-20T06:13:14+00:00 https://www.inovalon.com/publications/risk-score-cost-and-utilization-in-the-health-insurance-exchange-population-open-enrollment-vs-special-enrollment-periods-2/ 2017-05-20T06:13:14+00:00 https://www.inovalon.com/publications/population-health-status-of-beneficiaries-in-narrow-networks-2/ 2017-05-20T06:13:14+00:00 https://www.inovalon.com/publications/evaluation-of-aco-and-market-characteristics-impact-on-patient-experience-and-quality-of-care-improvement-in-pioneer-acos/ 2017-06-25T06:13:14+00:00 https://www.inovalon.com/publications/risk-score-cost-and-utilization-in-the-health-insurance-exchange-population-open-enrollment-vs-special-enrollment-periods/ 2017-06-25T06:13:14+00:00 https://www.inovalon.com/publications/population-health-status-of-beneficiaries-in-narrow-networks/ 2017-06-25T06:13:14+00:00 https://www.inovalon.com/publications/clinical-outcomes-following-catheter-or-surgical-ablation-of-atrial-fibrillation/ 2017-06-25T06:13:14+00:00 https://www.inovalon.com/publications/comparing-two-child-core-set-quality-measures-among-commercial-marketplace-and-managed-medicaid-populations-in-2015/ 2017-06-25T06:13:14+00:00 https://www.inovalon.com/publications/survey-based-patient-experience-and-quality-of-care-improvement-of-pioneer-acos/ 2017-06-25T06:13:14+00:00 https://www.inovalon.com/publications/evaluation-of-the-ability-of-advance-payment-acos-to-improve-quality-of-care-relative-to-a-comparison-group-using-claims-based-quality-measures/ 2017-06-25T06:13:14+00:00 https://www.inovalon.com/publications/using-data-driven-models-to-drive-optimal-post-acute-care-placement-and-reduce-readmission-risk-pc-3/ 2017-10-15T06:13:14+00:00 https://www.inovalon.com/publications/gender-disparities-in-use-of-cardiologist-care/ 2017-11-11T06:13:14+00:00 https://www.inovalon.com/publications/utilization-of-tvus-and-ffn-screening-antenatal-steroids-use-and-risk-of-preterm-delivery/ 2018-04-27T06:13:14+00:00 https://www.inovalon.com/publications/geographic-disparities-in-use-of-cardiologist-care/ 2018-05-08T06:13:14+00:00 https://www.inovalon.com/publications/using-aggregate-data-to-proxy-individual-level-characteristics-in-health-services-research-9-digit-zip-code-vs-census-block-group/ 2018-05-19T06:13:13+00:00 https://www.inovalon.com/publications/effect-of-chronic-condition-special-needs-plan-enrollment-on-outcomes-for-medicare-beneficiaries/ 2018-05-19T06:13:14+00:00 https://www.inovalon.com/publications/comparison-of-healthcare-utilization-by-disease-modifying-therapy-generation-among-individuals-diagnosed-with-multiple-sclerosis-after-one-year-of-initiating-therapy-in-the-united-states/ 2018-05-19T06:13:14+00:00 https://www.inovalon.com/publications/the-evaluation-of-adherence-to-treatment-and-real-world-outcomes-in-two-cohorts-of-patients-with-serious-mental-illness-smi/ 2018-05-19T06:13:14+00:00 https://www.inovalon.com/publications/the-evaluation-of-adherence-to-treatment-and-real-world-outcomes-in-2-cohorts-of-patients-with-serious-mental-illness-smi/ 2018-05-29T06:13:14+00:00 https://www.inovalon.com/publications/impact-of-cms-proposed-changes-to-medicare-advantage-hcc-risk-adjustment-model-for-payment-year-2019/ 2018-06-24T06:13:13+00:00 https://www.inovalon.com/publications/a-comprehensive-profile-of-the-high-cost-high-need-medicare-advantage-population/ 2018-06-24T06:13:13+00:00 https://www.inovalon.com/publications/effect-of-chronic-condition-special-needs-plan-enrollment-on-outcomes-for-medicare-beneficiaries-with-diabetes/ 2018-06-24T06:13:13+00:00 https://www.inovalon.com/publications/prevalence-and-likelihood-of-hospital-admission-and-readmission-in-patients-with-serious-mental-illness/ 2018-09-08T06:13:13+00:00 https://www.inovalon.com/publications/health-services-and-medication-utilization-among-people-with-cystic-fibrosis/ 2018-10-18T06:13:13+00:00 https://www.inovalon.com/publications/using-aggregate-data-to-proxy-individual-level-socioeconomic-characteristics-in-research-on-medication-adherence-9-digit-zip-code-vs-census-block-group/ 2018-10-22T06:13:13+00:00 https://www.inovalon.com/publications/effect-of-abuse-deterrent-opioid-formulary-coverage-on-utilization-and-the-risk-of-opioid-related-abuse/ 2018-10-22T06:13:13+00:00 https://www.inovalon.com/publications/the-relationship-between-type-of-lipid-lowering-therapy-risk-score-payments-and-healthcare-utilization-in-medicare-advantage-plans/ 2018-10-22T06:13:13+00:00 https://www.inovalon.com/publications/a-ready-to-use-liquid-glucagon-rescue-pen-for-severe-hypoglycemia-demonstrates-reduced-healthcare-payer-costs-in-a-budget-impact-model-2/ 2019-02-20T06:13:13+00:00 https://www.inovalon.com/publications/impact-of-abuse-deterrent-formulation-opioid-utilization-on-healthcare-resource-use-among-managed-medicaid-patients/ 2019-03-25T06:13:13+00:00 https://www.inovalon.com/publications/a-ready-to-use-liquid-glucagon-rescue-pen-for-severe-hypoglycemia-demonstrates-reduced-healthcare-payer-costs-in-a-budget-impact-model/ 2019-03-25T06:13:13+00:00 https://www.inovalon.com/publications/comparison-of-healthcare-utilization-among-managed-medicaid-individuals-diagnosed-with-multiple-sclerosis-treated-with-emergent-vs-established-disease-modifying-therapy-in-the-united-states/ 2019-03-25T06:13:13+00:00 https://www.inovalon.com/publications/predicting-falls-in-elderly-patients-using-claims-data-a-time-awarded-deep-learning-approach/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/leveraging-data-driven-insights-to-support-development-of-targeted-supplemental-benefits-under-newly-expanded-flexibilities-in-medicare-advantage-to-improve-outcomes-in-high-cost-high-need-beneficiar/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/healthcare-resource-utilization-expenditures-among-medicare-beneficiaries-newly-diagnosed-with-peripheral-t-cell-lymphoma-ptcl-a-retrospective-claims-analysis/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/a-budget-impact-analysis-of-cenobamate-for-the-treatment-of-refractory-partial-epilepsy/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/risk-adjusting-medicare-advantage-plan-performance-measures-for-social-determinants-of-health-are-dual-eligibility-and-disability-status-enough-2/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/how-should-data-on-social-determinants-of-health-be-best-used-to-improve-health-outcomes-and-reduce-disparities/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/comparing-utilization-cost-and-quality-in-dual-eligible-medicare-advantage-and-fee-for-service-medicare-beneficiaries/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/differences-between-enrollees-of-individual-versus-small-group-off-exchange-health-plans-under-the-affordable-care-act/ 2019-05-18T06:13:13+00:00 https://www.inovalon.com/publications/risk-adjusting-medicare-advantage-plan-performance-measures-for-social-determinants-of-health-are-dual-eligibility-and-disability-status-enough/ 2019-06-02T06:13:13+00:00 https://www.inovalon.com/publications/changes-in-incidence-of-febrile-neutropenia-hospitalization-fnh-following-myelosuppressive-chemotherapy-mc-in-medicare-2010-2017/ 2019-06-21T06:13:13+00:00 https://www.inovalon.com/publications/real-world-burden-of-illness-and-unmet-need-in-locally-advanced-or-metastatic-urothelial-carcinoma-following-discontinuation-of-pd-1-pd-l1-inhibitor-therapy-a-medicare-claims-database-analysis/ 2019-10-29T06:13:13+00:00 https://www.inovalon.com/publications/the-clinical-and-economic-impact-of-delays-in-reimbursement-for-select-novel-cancer-therapeutics-in-canada-italy-and-australia/ 2019-11-02T06:13:13+00:00 https://www.inovalon.com/publications/comparison-of-healthcare-resource-utilization-and-costs-of-type-2-diabetes-mellitus-t2dm-related-complications-in-medicare-beneficiaries-with-rheumatoid-arthritis-ra-and-t2dm-who-initiated-treatme/ 2019-11-08T06:13:12+00:00 https://www.inovalon.com/publications/comparison-of-healthcare-resource-utilization-hcru-and-costs-of-type-2-diabetes-mellitus-t2dm-related-complications-in-tnfi-experienced-medicare-beneficiaries-with-rheumatoid-arthritis-ra-and-t2/ 2019-11-08T06:13:12+00:00 https://www.inovalon.com/publications/comparison-of-infection-related-hospitalization-risk-and-cost-in-tnfi-experienced-medicare-beneficiaries-with-rheumatoid-arthritis-treated-with-abatacept-or-other-targeted-disease-modifying-anti-rheum/ 2019-11-08T06:13:12+00:00 https://www.inovalon.com/publications/comparison-of-infection-related-hospitalization-risk-and-cost-in-tnfi-experienced-medicare-beneficiaries-with-rheumatoid-arthritis-treated-with-abatacept-or-other-targeted-disease-modifying-anti-rhe-2/ 2019-11-08T06:13:13+00:00 https://www.inovalon.com/publications/the-mental-health-burden-of-patients-with-partial-onset-seizures/ 2019-12-06T06:13:12+00:00 https://www.inovalon.com/publications/medicare-patients-receiving-chimeric-antigen-receptor-t-cell-therapy-for-non-hodgkin-lymphoma-a-first-real-world-look-at-patient-characteristics-healthcare-utilization-and-costs-2/ 2019-12-07T06:13:12+00:00 https://www.inovalon.com/publications/real-world-treatment-patterns-and-overall-survival-among-medicare-fee-for-service-beneficiaries-newly-diagnosed-with-peripheral-t-cell-lymphoma-2/ 2019-12-07T06:13:12+00:00 https://www.inovalon.com/publications/medicare-patients-receiving-chimeric-antigen-receptor-t-cell-therapy-for-non-hodgkin-lymphoma-a-first-real-world-look-at-patient-characteristics-healthcare-utilization-and-costs/ 2020-02-19T06:13:12+00:00 https://www.inovalon.com/publications/malnutrition-quality-improvement-initiative-improves-malnutrition-measurement-and-care-results-from-a-hospital-learning-collaborative/ 2020-03-28T06:13:12+00:00 https://www.inovalon.com/publications/healthcare-burden-and-costs-of-recurrent-clostridioides-difficile-infection-in-the-medicare-population-2/ 2020-04-21T06:13:12+00:00 https://www.inovalon.com/publications/impact-of-post-operative-ileus-among-inpatients-undergoing-gastrointestinal-surgeries-in-the-united-states/ 2020-05-02T06:13:12+00:00 https://www.inovalon.com/publications/patient-characteristics-and-first-line-treatments-among-medicare-patients-with-metastatic-non-small-cell-lung-cancer-mnsclc/ 2020-05-16T06:13:12+00:00 https://www.inovalon.com/publications/estimating-excess-healthcare-costs-of-malnourished-patients-in-a-learning-collaborative-of-u-s-hospitals/ 2020-05-16T06:13:12+00:00 https://www.inovalon.com/publications/characteristics-of-users-and-prescribers-of-cyclin-dependent-kinase-4-6-inhibitors-cdk4-6i-among-medicare-and-non-medicare-patients-with-human-receptor-positive-human-epidermal-growth-factor-2-neg/ 2020-05-16T06:13:12+00:00 https://www.inovalon.com/publications/as-it-grows-medicare-advantage-is-enrolling-more-low-income-and-medically-complex-beneficiaries/ 2020-05-16T06:13:12+00:00 https://www.inovalon.com/publications/difference-in-nutrition-interventions-among-malnourished-hospitalized-patients/ 2020-05-30T06:13:12+00:00 https://www.inovalon.com/publications/medical-cost-of-care-by-line-of-treatment-lot-in-medicare-fee-for-service-ffs-beneficiaries-with-kras-mutated-metastatic-non-small-cell-lung-cancer-mnsclc/ 2020-10-09T06:13:12+00:00 https://www.inovalon.com/publications/biomarker-testing-patterns-and-use-of-targeted-therapy-in-medicare-fee-for-service-ffs-beneficiaries-newly-diagnosed-with-metastatic-non-small-cell-lung-cancer-mnsclc/ 2020-10-09T06:13:12+00:00 https://www.inovalon.com/publications/descriptive-real-world-payer-comparisons-of-exacerbation-frequency-and-healthcare-resource-utilization-after-chronic-obstructive-pulmonary-disease-diagnosis/ 2020-10-18T06:13:12+00:00 https://www.inovalon.com/publications/improving-malnutrition-diagnosis-at-an-academic-medical-center-a-nutrition-focused-quality-improvement-program/ 2020-10-18T06:13:12+00:00 https://www.inovalon.com/publications/healthcare-burden-and-costs-of-recurrent-clostridioides-difficile-infection-in-the-medicare-population/ 2020-10-20T06:13:12+00:00 https://www.inovalon.com/publications/evaluating-total-all-cause-and-copd-related-costs-by-comorbidity-burden-in-patients-with-medicare-fee-for-service/ 2020-10-20T06:13:12+00:00 https://www.inovalon.com/publications/disability-profiles-of-medicare-patients-with-acquired-thrombotic-thrombocytopenic-purpura-from-2010-to-2018/ 2020-10-20T06:13:12+00:00 https://www.inovalon.com/publications/assessment-of-healthcare-resource-use-by-comorbidity-burden-among-copd-patients-diagnosed-across-multiple-payer-settings/ 2020-10-20T06:13:12+00:00 https://www.inovalon.com/publications/real-world-treatment-patterns-and-overall-survival-among-medicare-fee-for-service-beneficiaries-newly-diagnosed-with-peripheral-t-cell-lymphoma/ 2020-10-20T06:13:12+00:00 https://www.inovalon.com/publications/current-practices-in-the-diagnosis-and-treatment-of-varicella-infections-in-the-united-states/ 2020-10-21T06:13:11+00:00 https://www.inovalon.com/publications/prevalence-of-severe-anemia-and-transfusion-risk-in-medicare-and-non-medicare-populations-with-ckd-stages-3-and-4/ 2020-10-22T06:13:12+00:00 https://www.inovalon.com/publications/development-of-a-claims-based-algorithm-to-identify-patients-with-agitation-in-alzheimers-dementia/ 2020-11-04T06:13:12+00:00 https://www.inovalon.com/publications/healthcare-resource-utilization-and-costs-in-congestive-heart-failure-90-day-episodes-within-the-bundled-payment-for-care-initiative-bpci-model-2-2016-2018/ 2020-11-13T06:13:12+00:00 https://www.inovalon.com/publications/thrombosis-and-risk-of-mortality-in-newly-diagnosed-high-risk-polycythemia-vera-an-analysis-of-the-medicare-claims-database-in-the-united-states/ 2020-12-05T06:13:11+00:00 https://www.inovalon.com/publications/burden-of-illness-among-medicare-and-non-medicare-populations-with-acquired-thrombotic-thrombocytopenic-purpura-2010-2018/ 2020-12-05T06:13:11+00:00 https://www.inovalon.com/publications/thrombotic-events-and-mortality-risk-in-patients-newly-diagnosed-with-intermediate-to-high-risk-essential-thrombocythemia-in-the-united-states/ 2020-12-05T06:13:11+00:00 https://www.inovalon.com/publications/burden-of-illness-and-outcomes-in-the-2nd-line-treatment-of-large-b-cell-lymphoma-a-real/ 2020-12-05T06:13:11+00:00 https://www.inovalon.com/publications/real-world-survival-among-patients-with-intermediate-to-high-risk-myelofibrosis-in-the-united-states-impact-of-ruxolitinib-approval/ 2020-12-05T06:13:11+00:00 https://www.inovalon.com/publications/cost-and-healthcare-utilization-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-real/ 2020-12-05T06:13:12+00:00 https://www.inovalon.com/publications/real-world-evidence-of-initial-medication-fills-after-chronic-obstructive-pulmonary-disease-copd-diagnosis-a-multiple-payer-analysis/ 2020-12-06T06:13:12+00:00 https://www.inovalon.com/publications/cost-and-healthcare-utilization-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-real-world-analysis-of-medicare-beneficiaries-receiving-chimeric-antigen-receptor-t-cell-vs-autologous-and-allo/ 2021-02-08T06:13:11+00:00 https://www.inovalon.com/publications/relationship-of-copd-exacerbation-burden-on-subsequent-healthcare-costs-in-a-medicare-ffs-claims-analysis/ 2021-04-13T06:13:11+00:00 https://www.inovalon.com/publications/real-world-healthcare-utilization-costs-and-overall-survival-among-patients-with-intermediate-to-high-risk-myelofibrosis-in-the-united-states-ruxolitinib-exposed-vs-unexposed-thrombotic-events-and/ 2021-04-13T06:13:11+00:00 https://www.inovalon.com/publications/mortality-healthcare-burden-and-costs-of-clostridioides-difficile-infections-and-recurrences-in-the-medicare-population/ 2021-04-13T06:13:11+00:00 https://www.inovalon.com/publications/direct-healthcare-resource-utilization-and-cost-in-managed-care-members-with-non-dialysis-dependent-chronic-kidney-disease-with-and-without-severe-anemia/ 2021-04-13T06:13:11+00:00 https://www.inovalon.com/publications/does-baseline-exacerbation-history-in-copd-predict-future-exacerbation-frequency-real-world-insights-from-multiple-us-insurers/ 2021-05-14T06:13:11+00:00 https://www.inovalon.com/publications/pneumonia-burden-and-exacerbations-a-large-real-world-evaluation-of-events-and-risks-among-chronic-obstructive-pulmonary-disease-copd-patients-in-the-united-states/ 2021-05-14T06:13:11+00:00 https://www.inovalon.com/publications/part-d-out-of-pocket-payments-in-medicare-beneficiaries-with-heart-failure-with-reduced-ejection-fraction/ 2021-05-15T06:13:11+00:00 https://www.inovalon.com/publications/incident-costs-of-dialysis-initiation-among-medicare-beneficiaries-with-advanced-chronic-kidney-disease/ 2021-05-17T06:13:11+00:00 https://www.inovalon.com/publications/characteristics-cost-and-health-care-resource-use-in-a-population-of-medicare-fee-for-service-ffs-patients-with-chronic-obstructive-pulmonary-disease-copd-who-also-experience-pneumonia/ 2021-05-17T06:13:11+00:00 https://www.inovalon.com/publications/healthcare-utilization-cost-and-quality-among-high-need-high-cost-medicare-beneficiaries-in-medicare-fee-for-service-versus-medicare-advantage-2/ 2021-05-17T06:13:11+00:00 https://www.inovalon.com/publications/a-real-world-comparison-of-mortality-healthcare-resource-utilization-and-cost-among-medicare-beneficiaries-with-clostridioides-difficile-infection-with-and-without-sepsis/ 2021-05-21T06:13:11+00:00 https://www.inovalon.com/publications/healthcare-utilization-cost-and-quality-among-high-need-high-cost-medicare-beneficiaries-in-medicare-fee-for-service-versus-medicare-advantage/ 2021-06-14T06:13:11+00:00 https://www.inovalon.com/publications/high-prevalence-of-social-determinants-of-health-compounds-burden-of-illness-in-patients-with-severe-mental-illness-2/ 2021-10-18T06:13:11+00:00 https://www.inovalon.com/publications/medicare-beneficiaries-with-serious-mental-illness-smi-have-high-prevalence-of-social-determinants-of-health-sdoh-2/ 2021-10-18T06:13:11+00:00 https://www.inovalon.com/publications/value-of-refill-adherence-to-first-line-ibrutinib-for-treatment-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-a-retrospective-claims-analysis/ 2021-10-18T06:13:11+00:00 https://www.inovalon.com/publications/antipsychotic-drug-use-and-healthcare-resource-utilization-among-alzheimers-dementia-patients-with-agitation-identified-from-a-novel-claims-based-algorithm/ 2021-10-18T06:13:11+00:00 https://www.inovalon.com/publications/a-real-world-comparison-of-mortality-healthcare-resource-utilization-and-cost-among-medicare-beneficiaries-with-clostridioides-difficile-infection-cdi-with-and-without-inflammatory-bowel-disease/ 2021-10-22T06:13:11+00:00 https://www.inovalon.com/publications/high-prevalence-of-social-determinants-of-health-compounds-burden-of-illness-in-patients-with-severe-mental-illness/ 2021-10-29T06:13:11+00:00 https://www.inovalon.com/publications/medicare-beneficiaries-with-serious-mental-illness-smi-have-high-prevalence-of-social-determinants-of-health-sdoh/ 2021-10-29T06:13:11+00:00 https://www.inovalon.com/publications/word-embedding-and-clustering-for-patient-centered-redesign-of-appointment-scheduling-in-ambulatory-care-settings/ 2021-10-30T06:13:11+00:00 https://www.inovalon.com/publications/linking-u-s-administrative-claims-data-and-electronic-health-records-to-describe-association-between-ambulatory-care-appointment-no-show-and-healthcare-resource-use-and-cost/ 2021-10-30T06:13:11+00:00 https://www.inovalon.com/publications/prevalence-and-recurrence-of-hyperkalemia-hk-in-medicare-patients-admitted-to-long-term-care-or-post-acute-care-ltc-pac-settings/ 2021-11-02T06:13:11+00:00 https://www.inovalon.com/publications/social-determinants-of-health-sdoh-and-healthcare-resource-utilization-hru-in-autosomal-dominant-polycystic-kidney-disease-adpkd-by-chronic-kidney-disease-ckd-stage/ 2021-11-02T06:13:11+00:00 https://www.inovalon.com/publications/treatment-persistence-among-medicare-beneficiaries-with-seropositive-rheumatoid-arthritis-initiating-biologic-or-targeted-synthetic-dmards/ 2021-11-03T06:13:11+00:00 https://www.inovalon.com/publications/healthcare-resource-utilization-and-costs-of-advanced-systemic-mastocytosis-among-medicare-fee-for-service-beneficiaries/ 2021-12-11T06:13:10+00:00 https://www.inovalon.com/publications/healthcare-resource-utilization-and-costs-of-medicare-fee-for-service-beneficiaries-newly-diagnosed-with-non-advanced-systemic-mastocytosis/ 2021-12-11T06:13:11+00:00 https://www.inovalon.com/publications/impact-of-race-ethnicity-and-socioeconomic-status-on-emergency-department-visits-in-patients-with-hepatocellular-carcinoma-2/ 2022-01-20T06:13:10+00:00 https://www.inovalon.com/publications/contemporary-unmet-needs-and-high-mortality-in-recurring-clostridium-difficile-patients-2/ 2022-03-29T06:13:10+00:00 https://www.inovalon.com/publications/social-determinants-of-health-healthcare-resource-utilization-and-costs-among-patients-with-schizophrenia-by-type-of-insurance/ 2022-03-29T06:13:10+00:00 https://www.inovalon.com/publications/drivers-of-pharmacy-spend-in-medicare-beneficiaries-newly-diagnosed-with-advanced-systemic-mastocytosis/ 2022-03-29T06:13:10+00:00 https://www.inovalon.com/publications/real-world-outcomes-of-minimally-invasive-epicardial-surgical-laa-exclusion-in-atrial-fibrillation-patients-with-high-risk-of-stroke-and-bleeding/ 2022-04-03T06:13:10+00:00 https://www.inovalon.com/publications/impact-of-social-determinants-of-health-sdoh-and-specialist-care-on-healthcare-resource-utilization-hru-and-costs-in-autosomal-dominant-polycystic-kidney-disease-adpkd/ 2022-04-06T06:13:10+00:00 https://www.inovalon.com/publications/a-real-world-comparison-of-mortality-health-care-resource-utilization-and-cost-among-medicare-beneficiaries-with-clostridioides-difficile-infection-cdi-with-and-without-inflammatory-bowel-disease/ 2022-05-11T06:13:10+00:00 https://www.inovalon.com/publications/identifying-disparities-in-health-outcomes-and-the-relationship-to-social-determinants-of-health/ 2022-05-15T06:13:10+00:00 https://www.inovalon.com/publications/total-cost-of-care-and-out-of-pocket-spending-for-medicare-fee-for-service-beneficiaries-with-advanced-melanoma-advanced-renal-cell-carcinoma-or-advanced-non-small-cell-lung-cancer-2/ 2022-05-15T06:13:10+00:00 https://www.inovalon.com/publications/economic-burden-of-metastatic-castration-resistant-prostate-cancer-by-line-of-treatment-in-medicare-beneficiaries-2014-2019-2/ 2022-05-15T06:13:10+00:00 https://www.inovalon.com/publications/characteristics-and-treatment-patterns-of-medicare-beneficiaries-with-triple-class-exposed-relapsed-refractory-multiple-myeloma-2/ 2022-05-15T06:13:10+00:00 https://www.inovalon.com/publications/contemporary-total-cost-of-care-among-medicare-patients-with-primary-and-recurrent-clostridioides-difficile-infection-2/ 2022-05-15T06:13:10+00:00 https://www.inovalon.com/publications/risk-factors-for-recurrences-of-clostridioides-difficile-infection-in-the-medicare-population-age-65-years-2/ 2022-05-15T06:13:10+00:00 https://www.inovalon.com/publications/treatment-patterns-in-patients-newly-diagnosed-with-schizophrenia-with-commercial-versus-medicaid-insurance-coverage-3/ 2022-05-15T06:13:10+00:00 https://www.inovalon.com/publications/contemporary-unmet-needs-and-high-mortality-in-recurring-clostridium-difficile-patients/ 2022-05-18T06:13:10+00:00 https://www.inovalon.com/publications/social-determinants-of-health-health-care-resource-utilization-and-costs-among-patients-with-major-depressive-or-bipolar-i-disorder-by-payer-type-2/ 2022-05-21T06:13:10+00:00 https://www.inovalon.com/publications/characteristics-and-treatment-patterns-in-medicare-patients-newly-diagnosed-with-schizophrenia-with-traditional-fee-for-service-versus-private-medicare-advantage-insurance-coverage/ 2022-05-31T06:13:10+00:00 https://www.inovalon.com/publications/social-determinants-of-health-health-care-resource-utilization-and-costs-among-patients-with-major-depressive-or-bipolar-i-disorder-by-payer-type/ 2022-05-31T06:13:10+00:00 https://www.inovalon.com/publications/treatment-patterns-in-patients-newly-diagnosed-with-schizophrenia-with-commercial-versus-medicaid-insurance-coverage-2/ 2022-06-04T06:13:10+00:00 https://www.inovalon.com/publications/impact-of-step-therapy-for-chronic-migraine-on-pharmacy-costs-and-healthcare-resource-utilization/ 2022-06-04T06:13:10+00:00 https://www.inovalon.com/publications/leveraging-equity-quality-measures-to-reduce-disparities-and-improve-outcomes/ 2022-06-28T06:13:10+00:00 https://www.inovalon.com/publications/characteristics-and-long-term-health-economic-outcomes-of-female-medicare-beneficiaries-with-fragility-fracture-receiving-skilled-nursing-facility-care/ 2022-09-09T06:13:10+00:00 https://www.inovalon.com/publications/data-driven-insights-to-improve-health-outcomes-and-health-equity/ 2022-09-16T06:13:10+00:00 https://www.inovalon.com/publications/navigating-rwe-constellations-inovalon-and-harvard-partner-to-turn-disparate-data-into-clear-actionable-information/ 2022-10-01T06:13:10+00:00 https://www.inovalon.com/publications/a-new-world-for-health-equity-reducing-health-disparities-utilizing-new-health-equity-measures/ 2022-10-01T06:13:10+00:00 https://www.inovalon.com/publications/unlock-the-value-of-healthcare-data-how-to-build-a-strong-data-governance-and-regulatory-compliance-framework-to-connect-health-data-and-improve-patient-outcomes/ 2022-10-10T06:13:10+00:00 https://www.inovalon.com/publications/cost-of-care-among-severe-persistent-asthma-patients-following-uncontrolled-status-in-the-u-s/ 2022-10-11T06:13:10+00:00 https://www.inovalon.com/publications/estimating-healthcare-expenditure-and-resource-utilization-in-second-and-third-lines-of-therapy-for-relapsed-refractory-multiple-myeloma/ 2022-10-11T06:13:10+00:00 https://www.inovalon.com/publications/post-pandemic-focus-on-health-disparities-medicare-advantage-plans-are-using-new-health-equity-measures-and-social-risk-data-to-drive-real-change/ 2022-11-01T06:13:10+00:00 https://www.inovalon.com/publications/social-determinants-of-health-addressing-what-drives-80-of-health-outcomes/ 2022-11-01T06:13:10+00:00 https://www.inovalon.com/publications/asthmatic-patients-are-at-risk-for-exacerbations-irrespective-of-control-maintenance-adherence-or-severity/ 2022-11-10T06:13:10+00:00 https://www.inovalon.com/publications/gaps-in-clinical-care-escalation-among-severe-persistent-asthma-patients-following-indicators-of-uncontrolled-status/ 2022-11-10T06:13:10+00:00 https://www.inovalon.com/publications/treatment-persistence-in-first-line-biologic-and-targeted-synthetic-dmard-users-with-dual-seropositive-ra-in-the-medicare-population-2/ 2022-11-10T06:13:10+00:00 https://www.inovalon.com/publications/real-world-effectiveness-and-economic-impact-associated-with-chimeric-antigen-receptor-t-cell-therapy-among-older-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/ 2022-12-10T06:13:10+00:00 https://www.inovalon.com/publications/management-of-patients-with-metastatic-castration-sensitive-prostate-cancer-in-the-real-world-setting-in-the-united-states/ 2022-12-21T17:32:35+00:00 https://www.inovalon.com/publications/real-world-survival-of-u-s-patients-with-intermediate-to-high-risk-myelofibrosis-impact-of-ruxolitinib-approval/ 2022-12-21T17:32:54+00:00 https://www.inovalon.com/publications/incremental-costs-associated-with-length-of-hospitalization-due-to-viral-pneumonia-impact-of-intensive-care-and-economic-implications-of-reducing-the-length-of-stay-in-the-era-of-covid-19/ 2022-12-21T17:33:13+00:00 https://www.inovalon.com/publications/a-retrospective-study-of-in-hospital-mortality-in-patients-with-idiopathic-pulmonary-fibrosis-between-2015-and-2018/ 2022-12-21T17:33:20+00:00 https://www.inovalon.com/publications/relapse-rates-in-patients-with-multiple-sclerosis-switching-from-interferon-to-fingolimod-or-glatiramer-acetate-a-u-s-claims-database-study/ 2022-12-21T17:35:20+00:00 https://www.inovalon.com/publications/real-world-effectiveness-and-economic-impact-associated-with-chimeric-antigen-receptor-t-cell-therapy-among-older-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-us0/ 2022-12-27T23:38:53+00:00 https://www.inovalon.com/publications/treatment-persistence-in-first-line-biologic-and-targeted-synthetic-dmard-users-with-dual-seropositive-ra-in-the-medicare-population/ 2023-01-19T23:06:27+00:00 https://www.inovalon.com/publications/total-cost-of-care-and-out-of-pocket-spending-for-medicare-fee-for-service-beneficiaries-with-advanced-melanoma-advanced-renal-cell-carcinoma-or-advanced-non-small-cell-lung-cancer/ 2023-01-19T23:50:37+00:00 https://www.inovalon.com/publications/economic-burden-of-metastatic-castration-resistant-prostate-cancer-by-line-of-treatment-in-medicare-beneficiaries-2014-2019/ 2023-01-19T23:52:44+00:00 https://www.inovalon.com/publications/characteristics-and-treatment-patterns-of-medicare-beneficiaries-with-triple-class-exposed-relapsed-refractory-multiple-myeloma/ 2023-01-19T23:53:52+00:00 https://www.inovalon.com/publications/contemporary-total-cost-of-care-among-medicare-patients-with-primary-and-recurrent-clostridioides-difficile-infection/ 2023-01-19T23:55:02+00:00 https://www.inovalon.com/publications/impact-of-race-ethnicity-and-socioeconomic-status-on-emergency-department-visits-in-patients-with-hepatocellular-carcinoma/ 2023-01-19T23:57:37+00:00 https://www.inovalon.com/publications/treatment-patterns-in-patients-newly-diagnosed-with-schizophrenia-with-commercial-versus-medicaid-insurance-coverage/ 2023-01-23T18:57:21+00:00 https://www.inovalon.com/publications/risk-factors-for-recurrences-of-clostridioides-difficile-infection-in-the-medicare-population-age-65-years/ 2023-01-23T18:57:40+00:00 https://www.inovalon.com/publications/racial-and-ethnic-disparities-in-treatment-of-uncontrolled-disease-among-severe-persistent-asthma-patients-an-analysis-of-medicare-fee-for-service-claims/ 2023-02-24T06:13:09+00:00 https://www.inovalon.com/publications/national-projection-of-u-s-patients-potentially-ineligible-for-existing-covid-19-treatments/ 2023-03-21T06:13:09+00:00 https://www.inovalon.com/publications/impact-of-social-determinants-of-health-on-access-to-device-aided-therapy-services-for-medicare-fee-for-service-beneficiaries-with-advanced-parkinsons-disease-3/ 2023-05-04T00:27:54+00:00 https://www.inovalon.com/publications/assessment-of-medically-attended-covid-19-patient-risk-profiles-and-health-care-resource-utilization-hcru-and-costs-in-the-u-s/ 2023-05-04T00:29:43+00:00 https://www.inovalon.com/publications/an-assessment-of-the-direct-and-indirect-costs-of-bladder-cancer-preceding-and-following-a-cystectomy-a-real-world-evidence-study/ 2023-05-04T00:31:58+00:00 https://www.inovalon.com/publications/treatment-patterns-and-healthcare-resource-utilization-in-patients-with-relapsed-refractory-multiple-myeloma-rrmm-classified-by-urbanicity-and-ethnicity/ 2023-05-04T00:32:41+00:00 https://www.inovalon.com/publications/long-covid-19-associated-with-5-fold-increase-in-total-medical-costs-and-greater-use-of-inpatient-and-outpatient-services-compared-to-non-long-covid-19-an-analysis-of-real-world-data/ 2023-05-04T00:33:24+00:00 https://www.inovalon.com/publications/impact-of-social-determinants-of-health-on-access-to-device-aided-therapy-services-for-medicare-fee-for-service-beneficiaries-with-advanced-parkinsons-disease/ 2023-05-07T06:13:09+00:00 https://www.inovalon.com/publications/characteristics-healthcare-resource-utilization-cost-and-quality-outcomes-of-medicare-beneficiaries-while-commercially-insured-before-and-after-transition-to-medicare-advantage-or-traditional-medic/ 2023-05-07T06:13:09+00:00 https://www.inovalon.com/publications/impact-of-availability-and-distance-to-device-aided-therapy-services-for-medicare-fee-for-service-beneficiaries-with-advanced-parkinsons-disease/ 2023-05-13T06:13:09+00:00 https://www.inovalon.com/publications/rates-of-asthma-exacerbations-among-severe-persistent-asthma-patients-in-the-us-following-event-indicating-uncontrolled-disease/ 2023-06-15T13:47:16+00:00 https://www.inovalon.com/publications/medicare-characteristics-treatment-cost-and-survival-in-triple-class-exposed-relapsed-or-refractory-multiple-myeloma/ 2023-06-15T13:49:25+00:00 https://www.inovalon.com/publications/impact-of-social-determinants-of-health-on-access-to-device-aided-therapy-services-for-medicare-fee-for-service-beneficiaries-with-advanced-parkinsons-disease-4/ 2023-11-09T12:13:19+00:00 https://www.inovalon.com/publications/survival-outcomes-in-us-medicare-patients-with-bronchiectasis-by-rate-of-baseline-exacerbations-6th-world-bronchiectasis-non-tuberculous-mycobacteria-ntm-conference-new-york-ny/ 2023-11-09T12:17:52+00:00 https://www.inovalon.com/publications/treatment-patterns-among-patients-with-bronchiectasis-by-baseline-exacerbations-6th-world-bronchiectasis-non-tuberculous-mycobacteria-ntm-conference-new-york-ny/ 2023-11-09T12:19:20+00:00 https://www.inovalon.com/publications/patient-characteristics-and-treatment-patterns-of-us-medicare-fee-for-service-beneficiaries-with-waldenstrom-macroglobulinemia/ 2023-11-09T12:19:58+00:00 https://www.inovalon.com/publications/economic-and-humanistic-burden-among-medicare-aged-women-with-fragility-fracture-in-the-united-states/ 2024-03-24T23:48:14+00:00 https://www.inovalon.com/publications/exacerbations-and-real-world-outcomes-eros-among-patients-diagnosed-with-copd-receiving-single-inhaler-triple-therapy-of-budesonide-glycopyrrolate-formoterol-fumarate/ 2024-03-24T23:58:40+00:00 https://www.inovalon.com/publications/clinical-and-economic-outcomes-in-patients-with-metastatic-urothelial-carcinoma-receiving-first-line-systemic-treatment-the-impact-uc-i-study/ 2024-03-25T01:19:09+00:00 https://www.inovalon.com/publications/real-world-evidence-of-car-t-cell-therapy-in-older-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-2/ 2024-03-25T01:20:24+00:00 https://www.inovalon.com/publications/disparities-in-lung-cancer-a-targeted-literature-review-examining-lung-cancer-screening-diagnosis-treatment-and-survival-outcomes-in-the-united-states/ 2024-03-25T01:21:26+00:00 https://www.inovalon.com/publications/the-increased-clinical-and-economic-burden-of-hyperkalemia-in-medicare-patients-admitted-to-long-term-care-settings/ 2024-03-25T01:22:19+00:00 https://www.inovalon.com/publications/comparative-effectiveness-of-carbidopa-levodopa-enteral-suspension-and-deep-brain-stimulation-on-pill-burden-reduction-in-medicare-fee-for-service-patients-with-advanced-parkinsons-disease/ 2024-03-25T01:25:53+00:00 https://www.inovalon.com/publications/adjusting-quality-measures-for-social-risk-factors-can-promote-equity-in-healthcare/ 2025-06-20T17:07:07+00:00 https://www.inovalon.com/publications/antipsychotic-medication-adherence-and-healthcare-services-utilization-in-two-cohorts-of-patients-with-serious-mental-illness/ 2025-06-20T17:07:08+00:00 https://www.inovalon.com/publications/association-between-formulary-coverage-and-use-of-abuse-deterrent-prescription-opioids-risk-for-abuse-or-overdose-and-associated-healthcare-resource-utilization/ 2025-06-20T17:07:11+00:00 https://www.inovalon.com/publications/budgetary-impact-on-a-u-s-health-plan-adopting-abiraterone-acetate-plus-prednisone-for-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer/ 2025-06-20T17:07:12+00:00 https://www.inovalon.com/publications/burden-of-illness-and-outcomes-in-2nd-line-large-b-cell-lymphoma-treatment-real-world-analysis-of-medicare-beneficiaries/ 2025-06-20T17:07:14+00:00 https://www.inovalon.com/publications/clinical-and-economic-burden-of-breakthrough-seizures/ 2025-06-20T17:07:16+00:00 https://www.inovalon.com/publications/clinical-burden-of-recurrent-clostridioides-difficile-infection-in-the-medicare-population-a-real-world-claims-analysis/ 2025-06-20T17:07:18+00:00 https://www.inovalon.com/publications/clinical-safety-and-economic-evidence-in-radioactive-iodine-refractory-differentiated-thyroid-cancer-a-systematic-literature-review/ 2025-06-20T17:07:19+00:00 https://www.inovalon.com/publications/comparative-effectiveness-of-fingolimod-versus-interferons-or-glatiramer-acetate-for-relapse-rates-in-multiple-sclerosis-a-retrospective-u-s-claims-database-analysis/ 2025-06-20T17:07:23+00:00 https://www.inovalon.com/publications/comparative-safety-of-atypical-antipsychotics-and-the-risk-of-pneumonia-in-the-elderly/ 2025-06-20T17:07:25+00:00 https://www.inovalon.com/publications/comparison-of-hospital-length-of-stay-and-supportive-care-utilization-between-patients-treated-with-cpx-351-and-73-for-therapy-related-acute-myeloid-leukemia-or-acute-myeloid-leukemia-with-myelodyspl/ 2025-06-20T17:07:27+00:00 https://www.inovalon.com/publications/cost-analysis-of-the-impact-of-caplacizumab-in-the-treatment-of-acquired-thrombotic-thrombocytopenic-purpura-from-a-u-s-hospital-perspective/ 2025-06-20T17:07:28+00:00 https://www.inovalon.com/publications/fesoterodine-prescription-fill-patterns-and-evaluation-of-the-yourway-patient-support-plan-for-patients-with-overactive-bladder-symptoms-and-physicians/ 2025-06-20T17:07:34+00:00 https://www.inovalon.com/publications/fetal-fibronectin-testing-and-pregnancy-outcomes-among-texas-medicaid-patients-at-risk-for-preterm-birth/ 2025-06-20T17:07:36+00:00 https://www.inovalon.com/publications/healthcare-resource-utilization-and-costs-of-recurrent-clostridioides-difficile-infection-in-the-elderly-a-real-world-claims-analysis/ 2025-06-20T17:07:39+00:00 https://www.inovalon.com/publications/health-related-quality-of-life-in-hemophilia-patients-with-inhibitors-and-their-caregivers/ 2025-06-20T17:07:41+00:00 https://www.inovalon.com/publications/how-a-malnutrition-quality-improvement-initiative-furthers-malnutrition-measurement-and-care-results-from-a-hospital-learning-collaborative/ 2025-06-20T17:07:42+00:00 https://www.inovalon.com/publications/measuring-the-value-and-return-on-investment-of-health-insurers-providing-non-medical-benefits-to-support-social-determinants-of-health-and-other-social-risk-factors/ 2025-06-20T17:07:46+00:00 https://www.inovalon.com/publications/medication-trajectory-and-treatment-patterns-in-medicare-patients-with-heart-failure-with-reduced-ejection-fraction/ 2025-06-20T17:07:48+00:00 https://www.inovalon.com/publications/mortality-healthcare-resource-utilization-and-cost-among-medicare-beneficiaries-with-clostridioides-difficile-infection-with-and-without-sepsis/ 2025-06-20T17:07:50+00:00 https://www.inovalon.com/publications/mortality-healthcare-use-and-costs-of-clostridioides-difficile-infections-in-older-adults/ 2025-06-20T17:07:52+00:00 https://www.inovalon.com/publications/outcome-evaluation-of-a-pharmacy-based-therapy-management-program-for-patients-with-cystic-fibrosis/ 2025-06-20T17:07:53+00:00 https://www.inovalon.com/publications/out-of-pocket-payments-for-part-d-covered-medications-by-medicare-fee-for-service-beneficiaries-with-heart-failure-with-reduced-ejection-fraction/ 2025-06-20T17:07:55+00:00 https://www.inovalon.com/publications/persistence-with-and-adherence-to-fingolimod-compared-with-other-disease-modifying-therapies-for-the-treatment-of-multiple-sclerosis-a-retrospective-u-s-claims-database-analysis/ 2025-06-20T17:07:57+00:00 https://www.inovalon.com/publications/primary-treatments-for-clinically-localized-prostate-cancer-a-comprehensive-lifetime-cost-utility-analysis/ 2025-06-20T17:07:58+00:00 https://www.inovalon.com/publications/providing-patients-with-pharmacogenetic-test-results-improves-adherence-to-statin-therapy-results-of-the-additional-kif6-risk-offers-better-adherence-to-statins-akrobats-trial/ 2025-06-20T17:08:02+00:00 https://www.inovalon.com/publications/quality-outcomes-healthcare-resource-utilization-and-costs-in-medicare-patients-with-chronic-heart-failure-with-reduced-ejection-fraction-with-and-without-a-worsening-event/ 2025-06-20T17:08:04+00:00 https://www.inovalon.com/publications/risk-factors-resource-utilization-and-cost-of-low-cardiac-output-syndrome-after-cardiac-surgery-a-cross-sectional-cohort-analysis/ 2025-06-20T17:08:11+00:00 https://www.inovalon.com/publications/treatment-patterns-costs-and-mortality-among-medicare-beneficiaries-with-cied-infection/ 2025-06-20T17:08:13+00:00 https://www.inovalon.com/publications/utilization-of-fetal-fibronectin-testing-and-pregnant-outcomes-among-women-with-symptoms-of-preterm-labor/ 2025-06-20T17:08:14+00:00 https://www.inovalon.com/publications/what-contributes-most-to-high-healthcare-costs-healthcare-spending-in-high-resource-patients/ 2025-06-20T17:08:16+00:00 https://www.inovalon.com/publications/off-label-use-of-semaglutide-in-the-united-states/ 2025-10-15T20:13:26+00:00 https://www.inovalon.com/publications/treatment-patterns-healthcare-resource-use-and-costs-among-us-patients-with-epidermal-growth-factor-receptor-mutated-metastatic-nonsmall-cell-lung-cancer/ 2025-10-15T20:19:52+00:00 https://www.inovalon.com/publications/comorbidity-burden-and-steriod-use-in-generalized-myasthenia-gravis/ 2025-10-15T20:29:05+00:00 https://www.inovalon.com/publications/gender-race-and-socioeconomic-disparities-on-surgical-device-aided-therapies/ 2025-10-15T20:33:15+00:00 https://www.inovalon.com/publications/gender-race-and-socioeconomic-disparities-on-surgical-device-aided-therapies-among-medicare-apd/ 2025-10-15T20:38:48+00:00 https://www.inovalon.com/publications/impact-of-demographics-and-social-determinants-of-health-on-hospitalization-costs-in-us-adults/ 2025-10-15T20:42:20+00:00 https://www.inovalon.com/publications/healthcare-costs-among-patients-diagnosed-with-estrogen-receptor-positive-breast-cancer/ 2025-10-16T14:44:08+00:00 https://www.inovalon.com/publications/impact-of-depression-on-treatment-patterns-and-outcomes-in-patients-with-newly-diagnosed-epilepsy/ 2025-12-22T17:25:14+00:00 https://www.inovalon.com/publications/impact-of-sdoh-on-hepatocellular-carcinoma-surveillance-treatment-and-costs/ 2026-01-07T17:39:48+00:00 https://www.inovalon.com/publications/treatment-patterns-healthcare-resource-utilization-and-costs-in-us-medicare-population-with-bronchiectasis/ 2026-01-07T17:49:03+00:00 https://www.inovalon.com/publications/communicating-rapid-diagnostic-test-results-to-the-healthcare-team-with-clinical-surveillance-software-a-u-s-community-hospital-case-study/ 2026-01-07T17:57:37+00:00 https://www.inovalon.com/publications/relationship-between-sdoh-and-hospitalizations-and-costs-mdd/ 2026-01-07T21:11:28+00:00 https://www.inovalon.com/publications/relationship-between-social-determinants-of-health-and-hospitalizations-and-costs-among-patients-with-bipolar-disorder-1/ 2026-01-08T15:55:33+00:00 https://www.inovalon.com/publications/exploratory-analysis-of-real-world-enrollment-patterns-among-dialysis-dependent-commercial-plan-members-with-end-stage-renal-disease/ 2026-01-08T16:10:19+00:00 https://www.inovalon.com/wp-content/uploads/2023/12/23-2625-Renalogic-Summary-Web-Report-Figure-1.jpg https://www.inovalon.com/wp-content/uploads/2023/12/23-2625-Renalogic-Summary-Web-Report-Table-1.jpg https://www.inovalon.com/publications/exacerbations-and-real-world-outcomes-after-single-inhaler-triple-therapy-of-budesonide-glycopyrrolate-formoterol-fumarate-among-patients-with-copd-results-from-the-eros-us-study/ 2026-01-08T16:27:36+00:00 https://www.inovalon.com/publications/development-of-a-social-determinants-of-health-insights-dashboard-to-support-organizations-in-advancing-health-equity/ 2026-01-08T16:38:44+00:00 https://www.inovalon.com/publications/differences-between-copd-patients-prescribed-revefenacin-and-tiotropium-bromide-post-hospitalization/ 2026-01-08T16:43:51+00:00 https://www.inovalon.com/publications/real-world-treatment-duration-of-atezolizumabcarboplatinetoposide-among-older-patients-with-extensive-stage-small-cell-lung-cancer-es-sclc-and-the-impact-of-performance-status-and-brain-metastases/ 2026-01-08T16:45:11+00:00 https://www.inovalon.com/publications/ldl-c-values-and-lipid-lowering-therapy-utilization-in-a-medicare-fee-for-service-ffs-population/ 2026-01-08T16:51:37+00:00 https://www.inovalon.com/publications/trends-in-opioid-use-disorder-diagnoses-hospitalizations-and-receipt-of-recommended-therapy/ 2026-01-08T16:55:29+00:00 https://www.inovalon.com/publications/healthcare-resource-utlization-and-costs-following-disease-progression-with-first-line-systemic-therapy/ 2026-02-12T17:15:11+00:00 https://www.inovalon.com/publications/minimally-invasive-epicardial-surgical-left-atrial-appendage-exclusion-for-atrial-fibrillation-patients-at-high-risk-for-stroke-and-for-bleeding/ 2026-02-12T17:16:30+00:00 https://www.inovalon.com/publications/real-world-outcomes-following-ibrutinib-dose-reduction-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/ 2026-02-12T17:23:44+00:00 https://www.inovalon.com/publications/comparative-effectiveness-and-healthcare-utilization-for-ambulatory-cardiac-monitoring-strategies-in-medicare-beneficiaries/ 2026-02-12T17:25:55+00:00 https://www.inovalon.com/publications/characteristics-healthcare-resource-utilization-cost-and-quality-outcomes-of-medicare-beneficiaries-while-commercially-insured-before-and-after-transition-to-medicare-advantage-or-traditional-medic-3/ 2026-03-13T18:23:52+00:00 https://www.inovalon.com/publications/gaps-in-care-among-uncontrolled-severe-asthma-patients-in-the-united-states/ 2026-03-13T18:26:57+00:00 https://www.inovalon.com/publications/gender-race-and-socioeconomic-disparities-on-surgical-device-aided-therapies-dats-among-medicare-beneficiaries-with-advanced-parkinsons-disease-apd/ 2026-03-13T18:28:47+00:00 https://www.inovalon.com/publications/prompt-initiation-of-budesonide-glycopyrronium-formoterol-reduces-exacerbations-and-cardiopulmonary-events-in-patients-with-copd-mitos-eroscp-study/ 2026-03-19T20:23:38+00:00 https://www.inovalon.com/publications/race-ethnicity-and-socioeconomic-position-in-emergency-department-utilization-in-patients-with-hepatocellular-carcinoma-2/ 2026-03-19T20:28:13+00:00 https://www.inovalon.com/publications/treatment-patterns-health-care-resource-utilization-and-costs-of-t-cell-vs-standard-thereapy/ 2026-03-19T20:30:40+00:00 https://www.inovalon.com/publications/geographic-disparities-and-access-to-device-aided-therapy-services-for-medicare-beneficiaries/ 2026-04-10T14:02:46+00:00 https://www.inovalon.com/publications/understanding-social-determinants-of-health-and-outcomes-in-patients-with-hereditary-angiodema/ 2026-04-10T14:04:18+00:00 https://www.inovalon.com/publications/promptly-escalating-to-budesonide-glycopyrronium-formoterol-from-dual-therapy-reduces-exacerbations-and-cardiopulmonary-events-in-patients-with-copd-mitos-eroscp-study/ 2026-04-10T15:09:08+00:00 https://www.inovalon.com/publications/chimeric-antigen-receptor-t-cell-access-in-patients-with-relapsedrefractory-large-bcell-lymphoma/ 2026-07-09T14:11:01+00:00 https://www.inovalon.com/publications/change-in-fracture-rate-among-patients-with-hypophosphatasia-following-initiation-of-asfotase-alfa-a-retrospective-u-s-claims-database-analysis/ 2026-08-11T14:56:36+00:00 https://www.inovalon.com/publications/assessment-of-oncology-care-model-participation/ 2026-08-17T15:02:09+00:00 https://www.inovalon.com/publications/continuous-glucose-monitoring-with-prandial-insulin-use-among-medicare-patients-with-type-2-diabetes-mellitus-and-reductions-in-diabetic-ketoacidosis-events/ 2026-08-27T13:33:03+00:00 https://www.inovalon.com/publications/healthcare-resource-utilization-and-economic-burden-among-patients-with-copd-following-cardiopulmonary-events-evidence-from-the-abacos-outcomes-study/ 2026-08-27T13:33:32+00:00 https://www.inovalon.com/publications/real-world-effectiveness-of-budesonide-glycopyrrolate-formoterol-fumarate-on-copd-exacerbations-and-healthcare-costs-by-eosinophil-level-results-from-the-u-s-arctos-study/ 2026-08-27T13:33:54+00:00 https://www.inovalon.com/publications/reduction-in-copd-exacerbations-following-prompt-triple-therapy-initiation-after-hospital-discharge-results-from-the-mitos-eros-discharge-study-u-s/ 2026-08-27T13:34:23+00:00 https://www.inovalon.com/publications/chronic-obstructive-pulmonary-disease-copd-exacerbations-before-and-after-completion-of-specialist-visits-results-from-the-duality-specialist/ 2026-08-27T13:34:38+00:00 https://www.inovalon.com/publications/clinical-and-social-drivers-of-triple-therapy-initiation-amongst-patients-with-copd-exacerbations-results-from-the-u-s-duality-disparities-study/ 2026-08-27T13:34:59+00:00 https://www.inovalon.com/publications/racial-ethnic-disparities-in-copd-related-healthcare-resource-utilization-and-expenditures-following-triple-therapy-initiation-results-from-the-u-s-duality-disparities-study/ 2026-08-27T13:35:14+00:00 https://www.inovalon.com/publications/a-comparative-assessment-of-travel-burden-and-productivity-loss-for-car-t-cell-therapy-and-bispecific-antibody-treatment-in-patients-with-relapsed-refractory-lbcl-using-u-s-claims-data/ 2026-08-27T13:35:49+00:00 https://www.inovalon.com/publications/receipt-of-sars-cov2-mrna-vaccine-prior-to-immune-checkpoint-inhibitor-therapy-associated-with-significantly-improved-overall-survival-across-multiple-metastatic-cancers-results-from-a-real-world-evi/ 2026-08-27T13:35:55+00:00 https://www.inovalon.com/publications/incremental-direct-and-indirect-costs-of-sjogrens-disease-in-the-united-states-a-retrospective-analysis-using-marketscan-databases/ 2026-08-27T13:36:18+00:00 https://www.inovalon.com/publications/flare-frequency-organ-damage-and-economic-burden-among-individuals-with-immunoglobulin-g4-related-disease-igg4-rd-in-the-united-states/ 2026-08-27T13:36:24+00:00 https://www.inovalon.com/publications/sociodemographic-and-clinical-characteristics-of-latanoprostene-bunod-initiators-among-medicare-fee-for-service-patients-with-open-angle-glaucoma-and-ocular-hypertension/ 2026-08-27T13:36:32+00:00 https://www.inovalon.com/publications/real-world-adherence-patterns-of-latanoprostene-bunod-ophthalmic-solution-0-024-in-medicare-patients-with-comorbid-dry-eye-disease-2/ 2026-08-27T13:37:08+00:00 https://www.inovalon.com/publications/medicare-advantage-vs-traditional-fee-for-service-medicare-different-populations-different-outcomes/ 2026-08-27T13:37:17+00:00 https://www.inovalon.com/publications/real-world-adherence-patterns-of-latanoprostene-bunod-ophthalmic-solution-0-024-in-medicare-patients-with-comorbid-dry-eye-disease/ 2026-08-27T13:37:27+00:00 https://www.inovalon.com/publications/missed-opportunities-for-pharmacist-intervention-among-medicare-fee-for-service-beneficiaries-with-myasthenia-gravis-a-real-world-claims-analysis/ 2026-08-27T13:37:38+00:00 https://www.inovalon.com/publications/real-world-treatment-patterns-discontinuation-and-treatment-switches-in-patients-with-generalized-myasthenia-gravis-gmg-a-retrospective-claims-analysis/ 2026-08-27T13:37:47+00:00 https://www.inovalon.com/publications/examining-the-impact-of-comorbid-depression-on-healthcare-utilization-cost-and-outcomes-in-patients-with-newly-diagnosed-epilepsy-in-the-u-s/ 2026-08-27T13:38:20+00:00 https://www.inovalon.com/publications/lipoproteina-impact-on-atherosclerotic-cardiovascular-disease-and-major-adverse-limb-events-among-patients-with-peripheral-artery-disease/ 2026-08-27T13:38:33+00:00 https://www.inovalon.com/publications/outcomes-of-inpatient-and-outpatient-chimeric-antigen-receptor-t-cell-therapy-in-newly-authorized-treatment-centers-in-the-united-states/ 2026-08-27T13:38:43+00:00 https://www.inovalon.com/publications/missed-opportunities-for-pharmacist-intervention-among-medicare-fee-for-service-beneficiaries-with-myasthenia-gravis-a-real-world-claims-analysis-2/ 2026-08-27T13:39:28+00:00 https://www.inovalon.com/publications/impact-of-depression-on-outcomes-and-treatment-patterns-in-patients-with-newly-diagnosed-epilepsy-a-retrospective-claims-analysis/ 2026-08-27T13:39:52+00:00 https://www.inovalon.com/publications/the-association-between-average-sales-price-decline-and-shortages-in-small-molecule-injectable-oncology-therapies-with-generic-competition/ 2026-08-27T13:40:17+00:00 https://www.inovalon.com/publications/impact-of-elevated-lipoproteina-on-cardiovascular-events-in-patients-with-premature-ascvd-a-nationally-representative-sample-of-u-s-medicare-medicaid-and-commercial-enrollees/ 2026-08-27T13:40:26+00:00 https://www.inovalon.com/publications/real-world-adherence-and-persistence-among-us-medicare-beneficiaries-initiating-advanced-lipid-lowering-therapies/ 2026-08-27T14:56:19+00:00 https://www.inovalon.com/publications/treatment-patterns-among-patients-with-neuromyelitis-optica-spectrum-disorder/ 2026-08-27T14:59:49+00:00 https://www.inovalon.com/publications/predictors-of-timely-hypertension-treatment-escalation-in-the-united-states/ 2026-08-27T15:04:02+00:00 https://www.inovalon.com/publications/z-codes-can-provide-important-data-on-social-determinants-of-health-and-improve-care-how-can-we-improve-utilization/ 2026-09-14T16:53:21+00:00